Adynovate

Groundbreaking gene therapies in store for hemophiliaTreatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
FDA OKs modified antihemophilic factor for hemophilia AFDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.